Efficacy of Sacral Nerve Modulation in Severe Refractory Constipation (CONSTIMOD)

July 22, 2015 updated by: University Hospital, Bordeaux
Subjects with refractory chronic constipation are offered two conventional therapeutic strategies: either medical treatment, either surgery (in the case of medication failure). Nevertheless, a procedure less invasive than surgery could be an alternative strategy: the sacral nerve modulation. This procedure consists in stimulating the nerves which control the contractions of the colon and so the defecation phenomenon. Several open trials have suggested that sacral nerve modulation may be effective in reducing constipation and related symptoms. The aim of this randomized clinical trial is to assess the efficacy of the sacral nerve stimulation in patients with constipation.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The prevalence of constipation is 2-27% in Western countries. For patients failing medical treatment (laxatives, biofeedback), a surgical solution may be considered (subtotal colectomy). But results are variable and it puts them at risk of functional sequelae.

Sacral nerve modulation is a minimally invasive procedure compared with the standard surgical support (colectomy) and reversible, which consists in two stages. First, a 3-week temporary stimulation test allows verifying the efficacy of neuromodulation. If the test is positive, the stimulating electrode is definitely implanted. Risks related to the procedure (infection, pain) are much smaller than those associated with a conventional surgical support.

Non comparative studies conducted with 19 and 62 patients showed that 40-73% of implanted patients have an improvement of their constipation and could benefit of permanent implantation with good results in medium term.

The primary objective of the investigators study is to evaluate the short-term efficacy (percentage of responders at 2 months) of sacral nerve modulation in the treatment of severe chronic constipation.

This is a cross-over designed, double-blinded, French multicenter clinical trial, including two periods: 2 months of stimulation ON and 2 months of stimulation OFF. Between these two periods, a 15-days period of "wash-out" will be respected during which all patients will be in OFF mode (4.5 months in total). This period of 4.5 months will be extended by a follow-up period of 7 months during which all patients will be treated (stimulation ON).

If this trial showed efficiency of this procedure, patients with severe refractory constipation could benefit of a sacral nerve modulation test before considering a surgical treatment.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bordeaux, France, 33075
        • Service d'hépato-gastroentérologie et oncologie digestive
      • Clermont Ferrand, France, 63000
        • Service d'hépato-gastroentérologie - CHU Estaing
      • Colombes, France, 92000
        • Service de gastroentérologie - AP HP
      • Grenoble, France, 38000
        • Service de Chirurgie générale - CHU de Grenoble
      • Lyon, France, 69000
        • Service d'exploration fonctionnelle digestive -Hospices Civils de Lyon
      • Marseille, France, 13000
        • Service de gastroentérologie - hopital nord -AP-HM
      • Nantes, France, 44000
        • : Clinique de chirurgie digestive et endocrinienne. Institut des Maladies de l'Appareil Digestif (IMAD
      • Rennes, France, 35000
        • SMAD CHU Pontchaillou -Rennes
      • Rouen, France, 76000
        • Service de physiologie digestive, urinaire, respiratoire et sportive - CHU de rouen
      • Tours, France, 37000
        • Service d'hépato-gastroentérologie et explorations fonctionnelles digestives - CHU de Tours
    • Limoges
      • CHU de Limoges, Limoges, France, 87000
        • Service d' Hépato-gastro-entérologie

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥ 18 years old
  • Constipation defined by at least two of the following criteria :

    • Frequency of 2 stools or less per week
    • Severe outlet constipation, i.e. need to use digital extraction or enemas more than 25% of time
    • Sensation of incomplete evacuation more than 25% of time
  • Refractory constipation since at least 1 year to medical treatment (drug treatment and/or biofeedback) conducted in the centre (failure or intolerance to laxative osmotic treatments, stimulants, and prucalopride) for which surgery is discussed
  • Patients supported in the centre for at least 3 months before inclusion
  • Patients having social security system
  • Patients having read and signed informed consent form

Exclusion Criteria:

  • Constipation secondary to ano-rectal malformation, surgical sequel, colorectal or anal organic lesions, or pelvi-perineal static disorder indicated for surgical treatment
  • Constipation secondary to neurological pathology and/or concomitant treatments intake (opiates, anticholinergic agents)
  • Partial colectomy history
  • Patients in whom implantation of stimulating electrode is impossible due to anatomical reasons (e.g. sacral agenesis)
  • Pregnant female patients or with childbearing potential without adequate contraceptive barrier (oestrogen-progesterone contraceptives or intra-uterine device)
  • Skin disease associated with a risk of infection - in the opinion of the investigator
  • Patient with pacemaker or defibrillator
  • Patient exposed to resonance magnetic imaging
  • Psychiatric disease incompatible with use of the treatment - in the opinion of the investigator
  • Patient misunderstanding oral and written French language
  • Patient participating to another study
  • Patients who don't complete the first diary without missing data (concerning items used to define the primary endpoint)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Arm on-off

After the definitive implantation, stimulators are placed in position OFF during 8 weeks.

Then all the stimulators are switched OFF for 15 days. Finally stimulators are switched ON for the second arm during 8 weeks

After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.

Then all the stimulators are switched OFF (both first and second arms) for 15 days.

Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks

EXPERIMENTAL: Arm off-on

After the definitive implantation, stimulators are placed in position ON during 8 weeks.

Then all the stimulators are switched OFF for 15 days. Finally stimulators are maintained in position OFF during 8 weeks

After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.

Then all the stimulators are switched OFF (both first and second arms) for 15 days.

Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of patients showing a positive response to sacral nerve stimulation at 2 months
Time Frame: 2 months of the stimualtion period
Percentage of patients showing a positive response to sacral nerve stimulation during the period " ON " compared with the period " OFF " based on an objective assessment of the number of feces and their characteristics
2 months of the stimualtion period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical characteristics, manometry data, Wexner score of responders to stimulation during the temporary stimulation test (period before the permanent implantation)
Time Frame: 3 weeks between temporary and permanent implantations
3 weeks between temporary and permanent implantations
Clinical characteristics, manometry data, Wexner score of responders to short-term stimulation
Time Frame: 2 months after permanent implantation
2 months after permanent implantation
Efficacy of neuromodulation
Time Frame: 1 year after permanent implantation
Efficacy of neuromodulation (percentage of positive responders) at 1 year
1 year after permanent implantation
Manometry data, Wexner, QoL and EVA scores, time of colonic transit of responders to prolonged stimulation
Time Frame: 1 year after permanent implantation
1 year after permanent implantation
To evaluate the investigator opinion about the neuromodulation response, using the patient diary.
Time Frame: 1 year after permanent implantation
1 year after permanent implantation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Frank ZERBIB, Professor, University Hospital, Bordeaux

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2012

Primary Completion (ACTUAL)

November 1, 2013

Study Completion (ACTUAL)

January 1, 2015

Study Registration Dates

First Submitted

June 11, 2012

First Submitted That Met QC Criteria

June 25, 2012

First Posted (ESTIMATE)

June 27, 2012

Study Record Updates

Last Update Posted (ESTIMATE)

July 23, 2015

Last Update Submitted That Met QC Criteria

July 22, 2015

Last Verified

July 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHUBX 2011/23

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Constipation

Clinical Trials on sacral nerve modulation

3
Subscribe